Canabidiol e suas indicações em psiquiatría
Barra lateral de artigos
Como Citar
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
##plugins.themes.bootstrap3.displayStats.downloads##
Societal impact
Conteúdo do artigo principal
Resumo
Esta revisão cobre a história, origem, síntese biológica do canabidiol (CBD), sua interação com o sistema canabinoide endógeno, apresentações para uso clínico, sua farmacocinética, tolerabilidade e evidências atuais de uso em psiquiatria. Além da origem do seu nome e dos detalhes da taxonomia botânica da cannabis, é interessante saber pelos estudos do pólen fóssil a cronologia e o percurso que ele percorreu ancestralmente até chegar à Europa e como começou seu estudo com a ideia lá para introduzi-lo na farmacopeia do momento e como um modelo para estudar distúrbios cerebrais como as psicoses. Jacques Joseph Moreau de Tours (1804-1884), psiquiatra francês, utilizou-o na forma de haxixe e estimulou o consumo experimental pelos intelectuais da época. Com base na suposição de que intelectuais e indivíduos educados eram sujeitos de estudo que poderiam fornecer relatos mais detalhados e floreados de experiências sob sua influência, Moreau de Tours primeiro concebeu que os efeitos da cannabis eram um paradigma experimental para o estudo das psicoses. Ele então experimentou seu uso terapêutico com resultados negativos. No caso do CBD, extraído da cannabis, a psiquiatría contemporânea poderia ver resultados mais promissores por meio de pesquisas clínicas em diferentes indicações.
Detalhes do artigo
Referências
Fuchs L. The great herbal of leonhart fuchs: De Historia Stirpium Comentarii insignes, 1542 (Notable Commentaries on the History of Plants). Stanford (California): Stanford University Press; 1999.
Small E. Evolution and classification of cannabis sativa (Marijuana, Hemp) in Relation to Human Utilization. Bot Rev. 2015;81:189.
McPartland JM, Guy GW. Cannabis may have evolved in the northeastern Tibetan Plateau, based on an interdisciplinary study of genetics, fossil pollen and ecology. En: Proceedings of the 26th Annual Symposium on the Cannabinoids. International Cannabinoid Research Society: Research Triangle Park. 2016. p. 61.
O’Shaughnessy WB. On the preparations of the Indian Hemp, or Gunjah: Cannabis indica their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Prov Med J Retrosp Med Sci 1843;5:363-9.
Moreau JJ. La Psychologie morbide dans ses rapport avec la philosophie de l’histoire ou l’influence des neuropathies sur le dynamisme intellectual. París: Masson, 1859.
Kim ES, Mahlberg PG. Immunochemical localization of tetrahydrocannabinol (THC) in cryofixed glandular trichomes of cannabis (Cannabaceae). Am J Bot 1987;84:336-42.
ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sciences 2005;78:539-48.
Hanus Lo, Meyer SM, Muñoz E, Taglialatela-Scafatti O, Appendino G. Phytocannabinoids: a unified critical inventory. Natural Product Reports 2016;1357-92.
Russo E. Beyond cannabis: plants and the endocannabinoid system. Trends in Pharmacological Sciences 2016;37:594-605.
McPartland JM, Matias I, Di Marzo V, Glass M. Evolutionary origins of the endocannabinoid system. Gene 2006;370:64-74.
Degenhart F, Stehle F, Kayser O. The biosynthesis of cannabinoids. En: Handbook of cannabis and related pathologies. 1.ª ed. Academic Press; 2017. Elsevier Inc. 13-23.
Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-47.
Marco EM, García Gutiérrez MS, Bermúdez-Silva FJ, Moreira FA, Guimarães F, Manzanares J, et al. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci 2011;5:63.
Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron 1963;19:2073-78.
Lafaye G, Karila L, Blecha L. Cannabis, cannabinoids and health. Dialogues Clin Neurosc. 2017;19:309-17.
Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics 2015;12:692-8.
Lu D, Potter DE. Cannabinoids and the cannabinoid receptors: an Overview. En: Handbook of cannabis and related pathologies. Elsevier; 2017.
Onaivi ES, Ishiguro H, Gong JP. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006;1074:514-36.
Hashimotodani Y, Ohno-Shosaku T, Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 2007;13:127-37.
Campos AC, Araújo-Moreira F, Villela-Gomes F, Aparecidad del Bel E, Silverira- Gimaraes F. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Phil Trans R Soc 2012;367:3364-78.
Laprairie RB, Bagher A, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 2015;172:4790-805.
United Nations Office on Drug and Crime. Convención Única de 1961 sobre Estupefacientes [Internet] [Consultado 3 de agosto de 2019]. Disponible en: https://www.unodc.org/pgl/convention_1961es.pgl.
United Nations Office on Drug and Crime. UNDOC. Convenio sobre Sustancias Sicotrópicas [internet] [Consultado 3 de agosto de 2019] Disponible en: https://www.undoc.org/pgl/convention_1971_es
Pavlovic R, Nenna G, Calvi L, Panseri S, Borgonovo G. Quality traits of “cannabidiol oils”: cannabinoids content, terpene fingerprint and oxidization stability of european comercially available preparations. Molecules 2018;23:1-5.
Senado de la República de Colombia. Ley 1787 [Internet] [Consultado el 3 de agosto de 2019] Disponible en: http://www.secretariasenado.gov.co/senado/basedoc/ley_1787_2016.html.
Ministerio de Salud de la República de Colombia. Decreto 613 de 2017. [Internet] Consultado el 3 de agosto de 2019] Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/decreto-613-de-2017.pdf.
Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardó FP, Pichini S. Evaluation of cannabinoids concentration a stability in standardized preparations of cannabis tea and cannabis oil by ultrahigh-performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med. 2017;55:1555-63.
Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA. Medicinal cannabis: principal cannabinoids concentration and their stability evaluated by a high-performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal 2016;128:201-9.
Giese MW, Lewis MA, Giese L, Smith KM. Development and validation of a reliable and robust method for the analysis of cannabinoids and terpenes in cannabis. J AOAC Int 2015:98:1503-22.
Bettiol A, Lombardi N, Crescioli G, Maggini V, Gallo E. Galenic preparations of therapeutic cannabis sativa differ in cannabinoids concentration: a quantitative analysis of variability and possible clinical implications. Frontiers Pharmacol 2019;9:1543.
Pellati F, Brighenti V, Sperlea J, Marchetti L, Bertelli D. New methods for the comprehensive analysis of bioactive compounds in Cannabis sativa L. (hemp). 2018;23:2639.
Booth JK, Bohlmann J. Terpenes in Cannabis Sativa: from plant genome to humans. Plant Science 2019;284:67-72.
Russo E. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharm 2011;163:1344-64.
Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O’Sullivan SE. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol 2019;1-13.
Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebocontrolled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 2008;32:1053-67.
Brown J, Winterstein A. Potential adverse drug events and drug drug interactions with medical and consumer cannabidiol use. J Clin Med 2019;8:989.
Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, et al. An entourage effect: inactive
endogenous fatty acid glycerol cannabinoid activity. Eur J Pharmacol 1998;353:23-31.
Abuhasira R, Bar-Lev Schleider L, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficay of medical cannabis in the elderly. European J Intern Med 2018;49:44-50.
Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic. 2.ª ed. Nueva York: Guilford; 2002.
Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 2016;41:80-122.
White CM. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacology 2019;59:923-34.
Zuardi AW, Suirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by THC in normal subjects. Psychopharmacology (Berl) 1982;76:245-50.
De Souza JA, Zuardi W, Garrido E. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004;29:417-26.
Lee JLC, Bertoglio LJ, Guimaraes FS, Stevenson CW. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. British J Pharmacol 2017;174:3242-56.
Bergamaschi M. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment: naïve social phobia patients. Neuropsychopharmacology 2011;36:1219-26.
Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Fr Psychol 2019;10:2466.
Elms L, Shannon S, Hughes S. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Alternative and Complimentary Med 2019;25:392-7.
Shannon S, Opila-Lehman J. Effectiveness of cannabidiol for pediatric anxiety an insomnia as part of a posttraumatic stress disorder: a case report. Perm J Fall 2016;20:16.
Van der Flier FE, Kwee CMB, Cath DC, Batelaan NM, Groenink L. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. BMC Psychiatry 2019;19:69.
Leweke FM, Piomelli D, Pahlisch F. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94.
McGuire P, Robson P, Cubala WJ. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 2018;175:225-31.
Makiol Ch, Kluge M. Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol. Aust N Z J Psychiatry 2019;53:262-5.
Barchel D, Stolar O, De Haan T, Ziv-Baran T, Saban. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-mobidities. Frontiers Pharmacol 2019;9:1521.
Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep 2019;9:200.
Parsaik AK, Mascarenhas SS, Khosh-Chashm D. Mortality associated with anxiolytic and hypnotic drugs: a systematic review and meta-analysis. Aust N Z J Psychiatry 2015;50:520-33.
Purcell Ch, Davis A, Moolman N. Reduction of benzodiacepine use in patients prescribed medical cannabis. Cannabis Cannabinoid Res 2019;0:1-5.
Gonzalez S, Cebeira M, Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 2005;81:300-18.
Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004;161:1967-77.
Yücel M, Lorenzetti V, Suo C. Hippocampal harms, protection, and recovery following regular cannabis use. Transl Psychiatry 2016;6:e710.
Vann RE, Gamage TF, Warner JA. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of delta (9)-tetrahydrocannabinol. Drug Alcohol Depend 2008;94:191-8.
Englund A, Morrison PD, Nottage J. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal: dependent memory impairment. J Psychopharmacol 2013;27:19-27.
Crippa JA, Hallak, JE, Machado-de-Sousa JP, Queiroz RH. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther 2013;38:162-4.
Scott S, Opila-Lehman J. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med 2015;14:31-5.
Solowij N, Broyd S, Beale C, Prick JA. Therapeutic effects of prolongued cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 2018;3:21-34.
Hurd Y, Spriggs S, Alishayev J, Winkel G, Gurgov K. Cannabidiol for the reduction of cue-induced craving an anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 2019;176:911-22.
Linares IMP, Guimaraes FS, Eckeli A. No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Front Pharmacol 2018;9:315.
Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA. Cannabidiol can improve complex sleep-related behaviors associated with rapid eye movement sleep behavior disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther 2014;39:564-6.
Megelin T, Ghorayeb I. Cannabis for restless legs syndrome: a report of six patients. Sleep Medicine 2017;36:182-3.
Zuardi AW, Guimaraes FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone, and cortisol in human volunteers. Braz J Med Biol Res 1993;26:213-7.